Market Leadership ProSomnus is recognized as a leading innovation in non-CPAP Obstructive Sleep Apnea therapy, with consistent inclusion in the Inc. 5000 list for fast growth, indicating a strong market presence and rising demand for alternative treatment options.

Expanding Product Portfolio The recent launch of EVO Guided and the upcoming Remote Patient Monitoring device demonstrate continuous product development, providing sales opportunities through added functionality and new treatment solutions tailored for diverse clinical needs.

Insurance Coverage With FDA clearance and coverage from major insurers, Medicare, and government healthcare plans covering over 200 million lives, ProSomnus devices are accessible to a broad patient base, enhancing prospects for expanding sales within insurance networks.

Strategic Partnerships Collaborations such as the partnership with US ENT highlight opportunities to develop targeted sales channels, integrate with leading healthcare providers, and expand treatment reach through strategic clinical alliances.

Growing Clinical Evidence ProSomnus’s clinical efficacy, safety, and adherence data, along with pilot studies on next-generation remote monitoring devices, position the company as a trusted innovator, encouraging medical professionals and institutions to adopt and recommend their solutions.